# Resource Summary Report

Generated by dkNET on Sep 7, 2026

## NCI-ADR-RES

RRID:CVCL_1452
Type: Cell Line

### Proper Citation

RRID:CVCL_1452

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_1452

**Proper Citation:** RRID:CVCL_1452

**Description:** Cell line NCI-ADR-RES is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** High grade ovarian serous adenocarcinoma

**Defining Citation:** PMID:9331090, PMID:9625176, PMID:10700174, PMID:11416159, PMID:15748285, PMID:16504380, PMID:17088437, PMID:18304946, PMID:19372543, PMID:20143388, PMID:21116879, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22628656, PMID:23933261, PMID:24279929, PMID:24670534, PMID:27377824, PMID:27807467, PMID:31733513, PMID:38861359

**Comments:** Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NCI-ADR-RES

**Synonyms:** NCI/ADR-RES, NCI.ADR.RES, NCIADR.RES, NCI/ADRRES, NCIADRRES, ADR-RES, MCF-7/ADR, MCF-7/ADR-RES, MCF-7/AdrR, MCF-7/Adr, MCF-7/adr, MCF-7ADR, MCF7-ADR, MCF7ADR, OVCAR-8/ADR, OVCAR8/ADR

**Cross References:** BTO:BTO_0004181, MCCL:MCC:0000310, ArrayExpress:E-MTAB-783, BioGRID_ORCS_Cell_line:390, BioSample:SAMN03151880, BioSample:SAMN03151881, cancercelllines:CVCL_1452, CancerTools:161022,

Cell_Model_Passport:SIDM00089, ChEMBL-Cells:CHEMBL3308057, ChEMBL-Targets:CHEMBL613829, Cosmic:687498, Cosmic:897420, Cosmic:905987, Cosmic:974233, Cosmic:1044218, Cosmic:1092617, Cosmic:1312358, Cosmic:1998459, GEO:GSM2099, GEO:GSM50197, GEO:GSM50260, GEO:GSM743473, GEO:GSM750832, GEO:GSM799367, GEO:GSM799430, GEO:GSM839041, GEO:GSM844614, GEO:GSM844615, GEO:GSM847073, GEO:GSM1153433, GEO:GSM1181271, GEO:GSM1181300, GEO:GSM2124672, IARC_TP53:21533, NCI-DTP:NCI/ADRRES, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, Progenetix:CVCL_1452, PubChem_Cell_line:CVCL_1452, SKY/M-FISH/CGH:2897, Wikidata:Q54907717

**ID:** CVCL_1452

**Hierarchy:** cvcl_1629

**Record Creation Time:** 20220427T220836+0000

**Record Last Update:** 20260905T181239+0000

## Ratings and Alerts

No rating or validation information has been found for NCI-ADR-RES.

Warning: Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234.
Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 363 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET .

Zhu H, et al. (2026) Rhamnetin Identified as a Potent Multidrug Resistance Reversal Agent From Xinjiang Euphorbia: Integrated Network Pharmacology, Molecular Simulation, and In Vitro Validation. Chemistry & biodiversity, 23(4), e01952.

Rahman I, et al. (2026) Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells. Bioengineering & translational medicine, 11(4), e70136.

Bischof K, et al. (2024) Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. Molecular oncology.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Kim CH, et al. (2023) Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells. Pharmaceuticals (Basel, Switzerland), 16(3).

Peng H, et al. (2023) Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. Bioactive materials, 19, 1.

Zhang T, et al. (2023) Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity. Drug delivery, 30(1), 2189118.

Wang C, et al. (2023) Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance. Marine drugs, 21(5).

Han E, et al. (2023) Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance. Molecules (Basel, Switzerland), 28(3).

Pan M, et al. (2023) Poly(l-Ornithine)-Based Polymeric Micelles as pH-Responsive Macromolecular Anticancer Agents. Pharmaceutics, 15(4).

Mukhtar MH, et al. (2023) Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters. Molecules (Basel, Switzerland), 28(8).

Shao W, et al. (2023) Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway. Scientific reports, 13(1), 1384.

Wang R, et al. (2023) Tumor microenvironment-responsive micelles assembled from a prodrug of mitoxantrone and 1-methyl tryptophan for enhanced chemo-immunotherapy. Drug delivery, 30(1), 2182254.

Jian FX, et al. (2023) Negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cells and patient prognosis after breast cancer surgery. BMC cancer, 23(1), 269.

Zhao S, et al. (2023) Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 32(4), 705.

Chen Z, et al. (2023) Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance. Frontiers in pharmacology, 14, 1133011.

Li Y, et al. (2023) Ethane groups modified DNA nanopores to prolong the dwell time on live cell membranes for transmembrane transport. Frontiers in chemistry, 11, 1148699.

Miri A, et al. (2023) Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line. Frontiers in oncology, 13, 1135836.

Abdelaziz MH, et al. (2023) A Novel Electrochemical Differentiation between Exosomal-RNA of Breast Cancer MCF7 and MCF7/ADR-Resistant Cells. Pharmaceuticals (Basel, Switzerland), 16(4).

Ju R, et al. (2023) Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing. Drug design, development and therapy, 17, 403.